Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically ...
BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating BHB810, a novel, ...
1d
Cancer's malignant remote control: How tumors reprogram liver fat metabolism to disarm immune cells
In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the ...
Deep within the cellular landscape, a quiet failure was taking place, impeding a potentially successful form of cancer ...
FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...
InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical ...
DUALITYBIO Inc. (HKEX: 09606; "DualityBio" or the "Company") today announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next ...
New Study Advances cDC1-Based Cancer Immunotherapy / Akata Saha, Allison Dyevoich, Bhakti Patel, Btnl2 Protein, cancer, CD4 T ...
Faron Enrolls First Patient in BEXAR Trial of Bexmarilimab for Metastatic Soft-Tissue Sarcoma / BEXAR, Bexmarilimab, Clever-1 ...
A new iPSC-derived dendritic cell platform uses patient tumor material to prime T cells against multiple cancer targets.
Radiotherapy augments immunotherapy, yet conventional 2 Gy x-ray fractions largely induce apoptosis, whereas robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results